About
T-and NK-cell Engagers for Cancer Therapy
Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company extends its pipeline and uses tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.
Identity
| Name | Immunorizon |
|---|---|
| Slug | immunorizon |
| Former names | ExploreBio1 |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJSx6-EJDA |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by Purple Biotech on Feb, 2023 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Yavne |
| HQ address | Yavne, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Business models
B2B
Tags
cancer-therapyimmunologyoncologyantibodiesbiotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}